185 related articles for article (PubMed ID: 32953626)
1. Surgery
Capozzi VA; Rosati A; Turco LC; Sozzi G; Riccò M; Chiofalo B; Vizzielli G
Gland Surg; 2020 Aug; 9(4):1112-1117. PubMed ID: 32953626
[TBL] [Abstract][Full Text] [Related]
2. Secondary cytoreductive surgery - viable treatment option in the management of platinum-sensitive recurrent ovarian cancer.
Felsinger M; Minar L; Weinberger V; Rovny I; Zlamal F; Bienertova-Vasku J
Eur J Obstet Gynecol Reprod Biol; 2018 Sep; 228():154-160. PubMed ID: 29957400
[TBL] [Abstract][Full Text] [Related]
3. Prediction Models for Complete Resection in Secondary Cytoreductive Surgery of Patients With Recurrent Ovarian Cancer.
Jiang C; Li Z
Front Oncol; 2021; 11():674637. PubMed ID: 34631517
[TBL] [Abstract][Full Text] [Related]
4. Update on the secondary cytoreduction in platinum-sensitive recurrent ovarian cancer: a narrative review.
Conte C; Fagotti A; Avesani G; Trombadori C; Federico A; D'Indinosante M; Giudice MT; Pelligra S; Lodoli C; Marchetti C; Ferrandina G; Scambia G; Gallotta V
Ann Transl Med; 2021 Mar; 9(6):510. PubMed ID: 33850907
[TBL] [Abstract][Full Text] [Related]
5. Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial.
Harter P; du Bois A; Hahmann M; Hasenburg A; Burges A; Loibl S; Gropp M; Huober J; Fink D; Schröder W; Muenstedt K; Schmalfeldt B; Emons G; Pfisterer J; Wollschlaeger K; Meerpohl HG; Breitbach GP; Tanner B; Sehouli J; ;
Ann Surg Oncol; 2006 Dec; 13(12):1702-10. PubMed ID: 17009163
[TBL] [Abstract][Full Text] [Related]
6. Performance of AGO score for secondary cytoreduction in a high-volume U.S. center.
Janco JM; Kumar A; Weaver AL; McGree ME; Cliby WA
Gynecol Oncol; 2016 Apr; 141(1):140-7. PubMed ID: 26836496
[TBL] [Abstract][Full Text] [Related]
7. Survival after secondary cytoreductive surgery and chemotherapy compared with chemotherapy alone for first recurrence in patients with platinum-sensitive epithelial ovarian cancer and no residuals after primary treatment. A registry-based study.
Szczesny W; Langseth H; Myklebust TÅ; Kaern J; Tropé C; Paulsen T
Acta Obstet Gynecol Scand; 2018 Aug; 97(8):956-965. PubMed ID: 29790149
[TBL] [Abstract][Full Text] [Related]
8. The efficacy of secondary cytoreductive surgery for recurrent ovarian, tubal, or peritoneal cancer in Tian-model low-risk patients.
So M; Miyamoto T; Murakami R; Abiko K; Hamanishi J; Baba T; Mandai M
J Gynecol Oncol; 2019 Nov; 30(6):e100. PubMed ID: 31576692
[TBL] [Abstract][Full Text] [Related]
9. External validation of two prediction models of complete secondary cytoreductive surgery in patients with recurrent epithelial ovarian cancer.
van de Laar R; Massuger LF; Van Gorp T; IntHout J; Zusterzeel PL; Kruitwagen RF
Gynecol Oncol; 2015 May; 137(2):210-5. PubMed ID: 25677063
[TBL] [Abstract][Full Text] [Related]
10. Secondary cytoreduction in ovarian cancer: who really benefits?
Giudice MT; D'Indinosante M; Cappuccio S; Gallotta V; Fagotti A; Scambia G; Petrillo M
Arch Gynecol Obstet; 2018 Nov; 298(5):873-879. PubMed ID: 30255344
[TBL] [Abstract][Full Text] [Related]
11. The Value of Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer and Application of a Prognostic Score.
da Costa AA; Valadares CV; Mantoan H; Saito A; Salvadori MM; Guimarães AP; Sanches SM; Achatz MI; Baiocchi G
Int J Gynecol Cancer; 2016 Mar; 26(3):449-55. PubMed ID: 26825830
[TBL] [Abstract][Full Text] [Related]
12. Peritoneal Surface Disease Severity Score (PSDSS), AGO-score and TIAN model in patients with platinum-sensitive recurrent ovarian cancer treated by cytoreductive surgery plus HIPEC.
Gómez-Ruiz ÁJ; González-Gil A; Gil J; Navarro-Barrios Á; Alconchel F; Gil E; Martínez J; Nieto A; Barceló F; Cascales-Campos PA
Clin Exp Metastasis; 2019 Oct; 36(5):433-439. PubMed ID: 31270731
[TBL] [Abstract][Full Text] [Related]
13. Secondary cytoreductive surgery in patients with isolated platinum-resistant recurrent ovarian cancer: a retrospective analysis.
Petrillo M; Pedone Anchora L; Tortorella L; Fanfani F; Gallotta V; Pacciani M; Scambia G; Fagotti A
Gynecol Oncol; 2014 Aug; 134(2):257-61. PubMed ID: 24910451
[TBL] [Abstract][Full Text] [Related]
14. Secondary cytoreductive surgery in recurrent epithelial ovarian cancer: A prognostic analysis with 103 cases.
Fan XM; Zhang J; Niu SH; Li KX; Song CZ
Int J Surg; 2017 Feb; 38():61-66. PubMed ID: 28027999
[TBL] [Abstract][Full Text] [Related]
15. Interval between secondary cytoreductive surgery and adjuvant chemotherapy is not associated with survivals in patients with recurrent ovarian cancer.
Jeong SY; Choi CH; Kim TJ; Lee JW; Kim BG; Bae DS; Lee YY
J Ovarian Res; 2019 Dec; 13(1):1. PubMed ID: 31892329
[TBL] [Abstract][Full Text] [Related]
16. A score system for complete cytoreduction in selected recurrent ovarian cancer patients undergoing secondary cytoreductive surgery: predictors- and nomogram-based analyses.
Bogani G; Tagliabue E; Signorelli M; Ditto A; Martinelli F; Chiappa V; Mosca L; Sabatucci I; Leone Roberti Maggiore U; Lorusso D; Raspagliesi F
J Gynecol Oncol; 2018 May; 29(3):e40. PubMed ID: 29533023
[TBL] [Abstract][Full Text] [Related]
17. Quality of Life in Platinum-Sensitive Recurrent Ovarian Cancer: Chemotherapy Versus Surgery Plus Chemotherapy.
Plotti F; Scaletta G; Aloisi A; Luvero D; Capriglione S; Miranda A; Montera R; De Cicco Nardone C; Terranova C; Angioli R
Ann Surg Oncol; 2015 Jul; 22(7):2387-94. PubMed ID: 25582738
[TBL] [Abstract][Full Text] [Related]
18. Long-Term Survival for Platinum-Sensitive Recurrent Ovarian Cancer Patients Treated with Secondary Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy (HIPEC).
Petrillo M; De Iaco P; Cianci S; Perrone M; Costantini B; Ronsini C; Scambia G; Fagotti A
Ann Surg Oncol; 2016 May; 23(5):1660-5. PubMed ID: 26714958
[TBL] [Abstract][Full Text] [Related]
19. The role of surgery in the management of patients with platinum-sensitive recurrent ovarian cancer: survey among Dutch gynecologists and medical oncologists.
van de Laar R; Zusterzeel PL; Van Gorp T; Ottevanger PB; Massuger LF; Kruitwagen RF
Gynecol Oncol; 2013 Dec; 131(3):561-6. PubMed ID: 24060415
[TBL] [Abstract][Full Text] [Related]
20. A Predictive Score for Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer (SeC-Score): A Single-Centre, Controlled Study for Preoperative Patient Selection.
Angioli R; Capriglione S; Aloisi A; Ricciardi R; Scaletta G; Lopez S; Miranda A; Di Pinto A; Terranova C; Plotti F
Ann Surg Oncol; 2015 Dec; 22(13):4217-23. PubMed ID: 25808099
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
